




18F-fluoride positron emission tomography/computed tomography and bone
scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate
cancer patients
study protocol for a multicentre, diagnostic test accuracy study
Fuglsang, Randi; Zacho, Helle D; Langkilde, Niels C; Petersen, Lars J
Published in:
B M C Cancer







Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Fuglsang, R., Zacho, H. D., Langkilde, N. C., & Petersen, L. J. (2016). 
18
F-fluoride positron emission
tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed,
high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study. B M C
Cancer, 16, [10]. https://doi.org/10.1186/s12885-016-2047-1
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
STUDY PROTOCOL Open Access
18F-fluoride positron emission tomography/
computed tomography and bone
scintigraphy for diagnosis of bone
metastases in newly diagnosed, high-risk
prostate cancer patients: study protocol for
a multicentre, diagnostic test accuracy study
Randi F. Fonager1, Helle D. Zacho1,3, Niels C. Langkilde2 and Lars J. Petersen1,3*
Abstract
Background: For decades, planar bone scintigraphy has been the standard practice for detection of bone
metastases in prostate cancer and has been endorsed by recent oncology/urology guidelines. It is a sensitive
method with modest specificity. 18F-fluoride positron emission tomography/computed tomography has shown
improved sensitivity and specificity over bone scintigraphy, but because of methodological issues such as
retrospective design and verification bias, the existing level of evidence with 18F-fluoride positron emission
tomography/computed tomography is limited. The primary objective is to compare the diagnostic properties of
18F-fluoride positron emission tomography/computed tomography versus bone scintigraphy on an individual
patient basis.
Methods/Design: One hundred forty consecutive, high-risk prostate cancer patients will be recruited from several
hospitals in Denmark. Sample size was calculated using Hayen’s method for diagnostic comparative studies. This
study will be conducted in accordance with recommendations of standards for reporting diagnostic accuracy
studies. Eligibility criteria comprise the following: 1) biopsy-proven prostate cancer, 2) PSA ≥50 ng/ml (equals a
prevalence of bone metastasis of ≈ 50 % in the study population on bone scintigraphy), 3) patients must be eligible
for androgen deprivation therapy, 4) no current or prior cancer (within the past 5 years), 5) ability to comply with
imaging procedures, and 6) patients must not receive any investigational drugs. Planar bone scintigraphy and
18F-fluoride positron emission tomography/computed tomography will be performed within a window of 14 days
at baseline. All scans will be repeated after 26 weeks of androgen deprivation therapy, and response of individual
lesions will be used for diagnostic classification of the lesions on baseline imaging among responding patients. A
response is defined as PSA normalisation or ≥80 % reduction compared with baseline levels, testosterone below
castration levels, no skeletal related events, and no clinical signs of progression. Images are read by blinded nuclear
medicine physicians. The protocol is currently recruiting.
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Discussion: To the best of our knowledge, this is one of the largest prospective studies comparing 18F-fluoride
positron emission tomography/computed tomography and bone scintigraphy. It is conducted in full accordance
with recommendations for diagnostic accuracy trials. It is intended to provide valid documentation for the use of
18F-fluoride positron emission tomography/computed tomography for examination of bone metastasis in the
staging of prostate cancer.
Keywords: Positron emission tomography/computed tomography, 18F-fluoride, Planar bone scintigraphy, Bone
metastases, Prostate cancer
Background
Prostate cancer is one of the most frequent cancers in
men [1]. It often metastasises to the bone, and this is as-
sociated with significant morbidity and mortality [2, 3].
According to current urology and oncology guidelines,
planar bone scintigraphy (BS) remains the standard
practice for detection of bone metastases in prostate
cancer [4–6]. BS has a high sensitivity for detection of
bone metastases in the staging of prostate cancer while
its specificity is moderate. Activity on BS may also repre-
sent benign conditions such as degenerative bone disor-
ders, traumas and inflammatory conditions [7]; these
conditions frequently occur in older men diagnosed with
prostate cancer [8].
Technical development within nuclear medicine bone
imaging has emerged since the introduction of BS, includ-
ing single photon emission computed tomography/com-
puted tomography (SPECT/CT), acquisition of BS, and
positron emission tomography/computed tomography
(PET/CT) with 18F-fluoride and 18F- or 11C-choline [9, 10].
The principle of 18F-fluoride is somewhat similar to BS
since it reflects regenerative bone processes, not the bone
metastasis itself. However, compared with the BS tracer,
18F-fluoride has a higher bone uptake, a faster blood clear-
ance and an improved target-to-background ratio [11]. Fur-
thermore, PET is associated with higher spatial resolution
than gamma-camera-based BS and likely may improve
diagnostic accuracy [11–13].
Retrospective studies, often with a limited number of
patients, have indicated that 18F-fluoride PET/CT is su-
perior to BS for detection of bone metastases in patients
with newly diagnosed prostate cancer and patients with
recurring prostate cancer. However, in the absence of
histopathological verification, the definitions of presence
or absence of bone metastases are essential for interpret-
ation of diagnostic comparative studies. A recent sys-
tematic review identified this issue as a key
methodological flaw in studies with bone-targeting PET
ligands [10]. Thus, the advantage of 18F-fluoride PET
versus BS for the diagnosis of bone metastases remains
to be shown in well-designed studies.
The primary aim of this diagnostic test accuracy study
is to compare 18F-fluoride PET/CT versus guideline-
recommended BS in diagnosing bone metastases in
newly diagnosed prostate cancer. The study protocol is
in full compliance with recommendations for diagnostic
test accuracy studies [14, 15]. Particular attention is
aimed at applying an optimised reference standard, i.e.,
confirming the presence or absence of bone metastases.
Methods/Design
Study objectives
The primary objective of this study is to assess the diag-
nostic accuracy of 18F-fluoride PET/CT for detection of
bone metastases compared with BS in newly diagnosed,
high risk, untreated prostate cancer patients on an indi-
vidual patient basis.
Secondary objectives are: 1) to assess the diagnostic
properties of SPECT/CT in comparison with BS and
18F-fluoride PET/CT, 2) to evaluate the diagnostic prop-
erties of all imaging modalities on the basis of individual
lesions, 3) to investigate the inter- and intra-observer
variation of SPECT/CT and 18F-fluoride PET/CT, and 4)
to investigate the predictive role of bone tumour load as
measured by 18F-fluoride PET/CT as a predictor of time
to loss of hormone sensitivity.
Study design
This study is designed as a multicentre, single-group, pro-
spective diagnostic test accuracy (DTA) study. It will be
conducted according to methodological criteria and rec-
ommendations as outlined by Standards for Reporting of
Diagnostic Accuracy studies (STARD) [14] and the Grad-
ing of Recommendation, Assessments, Development and
Evaluation (GRADE) [15].
Within a time window of 14 days, and no later than
7 days after initiation of androgen deprivation (ADT),
consenting patients will be examined by BS, SPECT/CT
and 18F-fluoride PET/CT. These scans are baseline ex-
aminations (Table 1). To assist in determination of
equivocal lesions on the baseline scan, the response to
treatment will be examined after 6 months of ADT.
Studies indicate regression of bone metastasis within
6 months following ADT in prostate cancer [16–21], not-
able decrease of baseline PSA within 6 weeks [16] and
testosterone levels below castration levels (≤50 ng/mL)
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within 4 weeks. The time period of 6 months should be suf-
ficient to demonstrate notable treatment effects without
any influence of the short-lasting, treatment-induced osteo-
blastic response called the flare phenomenon [22, 23].
Following 6 months of ADT, patients with a satisfac-
tory response will have all three scans repeated (Table 1).
A satisfactory ADT response is defined as: 1) normalisa-
tion of PSA or at least 80 % reduction of baseline PSA
levels, 2) plasma-testosterone below castration levels, 3)
no skeletal-related events since baseline, and 4) no clin-
ical, biochemical, or other indication of disease progres-
sion. The imaging response to satisfactory ADT will
guide the readers to classify metastasis and benign le-
sions on the baseline scans (Fig. 1). ADT affects both
the primary tumour and bone metastatic cancer cells,
and bone metastases will therefore regress or become
indistinguishable on imaging following satisfactory ADT
[29, 30] (Fig. 2). The patients will be followed clinically
until the cancer has progressed to castration-resistant
prostate cancer according to criteria from the European
Association of Urology [26].
Study population
A total of 140 consecutive patients will be recruited.
Eligibility criteria comprise: 1) biopsy-proven prostate
cancer, 2) PSA ≥50 ng/ml, 3) patients must be eligible
for androgen deprivation therapy, 4) no current or
prior cancer (within the past 5 years), 5) ability to
comply with imaging procedures, and 6) no investiga-
tional drugs. Based on existing data, the prevalence of
bone metastases in this population is expected to be
approximately 50 % on BS [8]. A bone metastasis-
enriched population was selected to optimise sample
size while still taking into consideration obtaining a
reference test. Inclusion of patients scheduled for
prostatectomy or radiation therapy would interfere
with the definitions of the reference standard and
presence or absence of bone metastasis (see Rationale
for design).
Subjects will be recruited consecutively from, at
present, four urological departments in Denmark.
Ethical considerations
This DTA study will be conducted according to the
principles of the Helsinki II Declaration. The patients re-
ceive oral and written information about the study and
provide written informed consent prior to any study-
related procedures. The study protocol is approved by
the North Denmark Region Committee on Health
Research Ethics (N-20130068) and the Danish Data
Protection Agency.
Imaging procedures
Planar bone scintigraphy and SPECT/CT
BS and SPECT/CT is conducted in accordance with
current institutional recommendations which are in line
with international guidelines [27]. Whole body BS is per-
formed 2 h after injection of approximately 750 M
Becquerel (MBq) 99mTc-labelled diphosphonate. Three-
bed SPECT/CT torso-scan (from vertex to mid-thigh) is
performed immediately after BS. The CT component
used with SPECT as well as with PET is a low-dose ac-
quisition primarily used for attenuation correction and
anatomical localisation.
18F-fluoride PET/CT
18F-fluoride PET/CT will be conducted in accordance
with recent American and German guidelines [28, 29].
PET/CT will be performed approximately 30 min after
intravenous administration of 200 MBq 18F-fluoride. A
total of 7 to 9 bed positions are performed with an ac-
quisition time of 2.5 min per bed position resulting in a
scan from the skull to mid-thigh.
Image analysis
Diagnostic accuracy is primarily analysed on a patient-
basis. All images are evaluated by a reading committee of
two readers who must be board certified in Nuclear Medi-
cine and/or Radiology and experienced with the imaging
modality. Readers will have access to PSA, T-stage,
Gleason grade, and a standard questionnaire filled out by
the patients. The amount of clinical information will be
minimised to reduce reading bias but the amount of infor-
mation will be sufficient to reflect clinical practice and
thus, will present the generalisability of the findings. The
questionnaire contains information about any artificial
joint replacements, prior surgeries to joint or bone, prior
skeleton or joint infections, known degenerative or in-
flammatory bone diseases, recent trauma to the skeleton,
and location and duration of any bone pain [8].
All lesions, or a representative sample if a large num-
ber of lesions are present, are first classified independ-
ently by each reader for malignancy using a
dichotomous scale as well as a numerical rating scale
which includes an equivocal rating option [30]. The
latter scale will be used primarily to determine
Table 1 Overview of study procedures
Baseline Follow-up
Visit number: 1 1a 2 2a
Day: 0 1 180 181
Androgen deprivation theapy Ongoing
Planar bone scintigraphy X X
SPECT/CT X X
18F-fluoride PET/CT X X
PSA X X
P-testosterone X X
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observer agreement. Eventually, the readers will reach
consensus for the dichotomous outcome. If consensus
cannot be reached, a third reader will be included and
a majority rule will apply. Lesion analysis is then sum-
marised on an individual patient basis. The exact
measurement scales and how to handle patients with
multiple bone lesions will be stated in a reader manual
and the statistical analytical plan (see Data Analysis).
Readers may participate in the reading committee for
more than one imaging modality.
Image evaluation procedure
Baseline images
A standardised protocol for image analysis will be
used. As a rule of thumb, the following applies: 1)
lesions located in the pelvis or spine, which are not
directly joint-related (e.g., sacroiliac joint, facet
joints, or discs) are malignant, 2) isolated lesions
outside the pelvic/hip area, with no simultaneous
uptake in the axial skeleton, are benign; however, if
concurrent metastases in the axial skeleton are
present, malignancy is considered, 3) lesions in
hands, feet, and at large joints (shoulders, elbows,
hips joints, and knees) are benign.
Even though the use of low-dose CT is primarily for at-
tenuation correction and anatomical localisation, any diag-
nostic information obtained from the CT scan will be used,
e.g., the characteristics and extent of osteosclerotic and
osteolytic lesions, lesion irregularity, etc.
Follow up images
Once the readers have assessed the baseline scan for
a patient (and the case report form has been signed),
they read baseline and 6 month images for that pa-
tient side-by-side. Based on a subjective evaluation of
lesion characteristics at baseline along with lesion
Fig. 1 Schematic drawing of the treatment response of planar bone scintigraphy and 18F-fluoride PET/CT. a Baseline imaging with planar bone
scintigraphy (BS); BS shows two lesions in the pelvic region, one lesion in a vertebra, and lesions at both hip joint surfaces. b 18F-fluoride PET/CT
demonstrate two additional lesions that were not detected by BS (marked with blue circle). c Post-ADT imaging with BS. d Post-ADT imaging
with 18F-fluoride PET/CT. All lesions detected by BS, which are not located near joints, showed partial (n = 2) or complete (n = 1) regression and
thus were defined as bone metastases. All the lesions detected by 18F-fluoride PET/CT, which are not located near joints, regressed (n = 5). Thus,
18F-fluoride PET/CT detected two lesions that were not detected by BS, these are defined as true positive on18F-fluoride PET/CT and consequently
as false negative on BS. ADT androgen deprivation therapy. The illustration is copyright of Nuclear Medicine Aalborg
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changes from baseline to 6 months, the readers will
classify individual lesions as malignant or benign. In
equivocal or inconsistent cases, baseline and follow-
up images from all three imaging modalities will be
read and evaluated together. Any new lesions seen on
the follow-up scan but not observed on the baseline
image on any imaging modalities will not be
classified.
Final diagnosis
A map of lesions identified by all imaging modalities
will be drawn. Some lesions may be observed on all im-
aging modalities, while other lesions may be observed
only in one or two modalities. The lesions will be ana-
lysed per modality and combined and classified as: 1)
True positive: A lesion that was defined as M+ on the
baseline image and that responded to ADT on on any
Fig. 2 Pre- and post-androgen deprivation therapy images from planar bone scintigraphy (anterior view). Anterior images from planar bone
scintigraphy of one patient at baseline (a) and after 6 months of satisfactory androgen therapy (b). PSA decreased from 92 ng/mL at baseline to
8.8 ng/mL (90 % reduction), and plasma-testosterone decreased from 1.7 to 0.07 ng/ml. All lesions initially suspected of malignancy in the axial
skeleton demonstrated partial or complete regression, whereas lesions in large joints and small joints in the hands and feet were stable or
progressed. The activity in the left elbow region is an artifact caused by contamination at tracer injection
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follow-up images, 2) False positive: A lesion that was
defined as M+ on the baseline image but did not re-
spond to ADT in any of the imaging modalities, 3) False
negative: A lesion that was not identified on one im-
aging modality at baseline, but turned out to eventually
be classified as M+ on other imaging modalities, e.g. a
lesion that was not detected by BS but detected and
classified as true positive on 18F-fluoride PET/CT will
be classified as false negative on BS, see Fig. 1, and 4)
True negative: A lesion that was not identified on one
imaging modality at baseline, and was eventually classi-
fied as M- on other imaging modalities as well. Patients
with at least one lesion characterised as malignant by
any imaging modality will be classified as malignant on
an individual patient basis. How to handle inconsistent
responses between imaging modalities will be specified
in the statistical analysis plan. For lesions-based ana-
lysis, final diagnosis is determined by the same criteria
as for the patient-based analysis, as described above.
Sample size considerations
Sample size calculations are based on recommendations
from Hayen et al. for DTA studies [31]. Weighed means
of sensitivity and specificity of BS, SPECT/CT and 18F-
fluoride PET/CT were calculated based on reported
values in published clinical trials. The power calculation
showed that 114 patients are needed to identify a signifi-
cant difference between the false positive fractions (i.e.,
1-specificity) of BS and SPECT/CT versus 18F-fluoride
PET/CT with a type I error of 5 % and a type II error of
20 %, assuming a prevalence of bone metastases of 50 %
on BS. A total of 140 patients will be recruited to ac-
count for possible dropouts. Calculated weighed mean
values of true positive fractions (sensitivity) for BS,
SPECT/CT and 18F-fluoride PET/CT are very similar
(0.87, 0.90, and 0.87, respectively), which indicated that
more than 5,000 patients were needed to demonstrate a
significant difference in sensitivity among the methods.
Data analysis
A detailed statistical analysis plan, including consider-
ations for secondary endpoints, will be issued prior to
analysis. Data analysis will primarily focus on the diag-
nostic accuracy of BS and 18F-fluoride PET/CT. Sensitiv-
ity, specificity, positive and negative predictive values,
and likelihood ratios will be calculated for each imaging
modality with 95 % confidence intervals and will be
compared using the McNemar test, with P < 0.05 being
statistically significant.
Quality assessment
All scans are performed according to local practices which
are in line with international guidelines [29]. No detailed
requirement for accreditation of the equipment prior to
baseline is applied. However, the image quality of the ap-
plied scanners is compared in order to adjust for any rele-
vant differences in scanner performances in the statistical
analysis. The following performance measurements will
be obtained: data from the initial installation of the
scanner, data from the most recent quality control, and
prospective, study-related data from phantom scans.
Rationale for design
Patient selection
The GRADE recommendations state that valid DTA
studies should include representative and consecutive
patients [15]. This study is conducted in bone-
metastasis-enriched patients with prostate cancer due to
the ADT-assisted definition of the presence or absence
of bone metastasis. However, inclusion of low-risk pa-
tients as well as patients undergoing curatively intended
treatment would interfere with sample size calculations
and/or methodological issues with regard to the validity
of the reference standard. For example, persistently ele-
vated PSA levels following radical prostatectomy may
arise from the remnant primary tumour or lymph nodes,
as well as bone metastases. In addition, the PSA re-
sponse in patients receiving curatively intended radiation
therapy may be very slow, may be masked by concomi-
tant ADT; any progression some years after post-therapy
cannot be attributed with certainty to bone metastases
at the time of diagnosis.
DTA design
This DTA protocol and the planned manuscript is and
will be in full compliance with the 25 items of the
STARD guideline, including title and abstract, introduc-
tion, methods (participants, test methods, statistical ana-
lysis), and results. Similar to the CONSORT statement
of reporting of randomised controlled trials and the
PRISMA statement for reporting of systematic reviews
(see www.equator-network.org), STARD is a guideline
for reporting of DTA studies. The trial methodology laid
down in the STARD recommendations have also been
endorsed by the Cochrane organisation for systematic
reviews of diagnostic test studies. It is generally accepted
that properly conducted DTA trials are a requirement
before the conduct of randomised controlled trials to
study the impact of different diagnostic strategies on pa-
tient outcome [15, 32]. This DTA study is completely
compliant with STARD criteria [14]. Compliance with
and reporting of STARD items in DTA studies has been
slowly increasing since the introduction of STARD; how-
ever, according to Korevaar et al., as of 2014, reporting
of STARD could still be improved [33].
According to GRADE, patient-important outcomes can
be inferred on the basis of diagnostic test accuracy. This
means that if this DTA study demonstrates that the
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diagnostic accuracy is significantly improved by 18F-fluor-
ide PET/CT compared with BS then more cases of pros-
tate cancer will be correctly classified according to disease
stage, thus ensuring optimal management of the disease.
On the contrary, if the diagnostic accuracy is equal for
both modalities but 18F-fluoride PET/CT is more conveni-
ent for the patient (e.g., shorter time from injection to
scan and shorter scan time), these results will ensure that
the course of diagnosis is optimal.
Discussion
Early and correct diagnosis of bone metastases in pros-
tate cancer is important for clinical decision making.
Thus, sensitive and specific diagnostic techniques are re-
quired. BS remains the guideline-recommended method
for staging of bone metastasis in prostate cancer, but it
can be debated if this is appropriate in light of emerging,
interesting methods such as 18F-fluoride PET/CT and
multi-parametric magnetic resonance imaging [34].
The decision to select an appropriate diagnostic method
preferably should be made based on evidence-based rec-
ommendations. However, in 2011, Poonacha et al. [35]
published a study examining the level of evidence under-
lying clinical recommendations from the National
Comprehensive Cancer Network. It was revealed that no
recommendations for prostate cancer staging, as well as
for any other diagnostic recommendations across tumour
types, were based on level I evidence. Small series and
retrospective studies have indicated that 18F-fluoride PET/
CT is significantly better than BS; however, the superiority
of 18F-fluoride PET/CT remains to be shown in properly
designed and well-powered clinical trials [9, 13, 36–38].
The level of evidence among previously published studies
is quite low (level 3b according to the Oxford Centre for
Evidence-based Medicine) [10]. The low level of evidence
in diagnostic medicine is a general phenomenon [35], but
the issues have been highlighted on several occasions re-
garding imaging [33]. We believe that a large DTA study
performed in accordance with STARD recommendations
will allow us to make firm conclusions about the diagnos-
tic properties and potential advantages of 18F-fluoride
PET/CT versus guideline-recommended BS.
We realise that strict methodological criteria and high
quality procedures may conflict with generalisability of
the findings in clinical practice. Therefore, images are
read with key clinical information as would be available
in clinical situations. The risk of reading bias is present
but the reading conditions are fully described; thus, all
stakeholders can judge the results based on his or her
premises. Similarly, gamma cameras and PET/CT scan-
ners are not accredited or standardised prior to recruit-
ment as required in some multicentre trials, e.g., those
from the European Organization on Research and Treat-
ment of Cancer. Instead, we aimed at comparing the
imaging modalities as they are used in daily clinical
practice rather than comparing the imaging modality per
se under optimal instrumental settings.
18F-fluoride PET/CT has already been routinely applied
for detection of bone metastases in prostate cancer in
some clinics. However, it is important to note that in the
most recent guidelines from the National Comprehensive
Cancer Network on prostate cancer, panelists express
their concern about the inappropriate use of expensive
PET imaging in the clinical setting [39], e.g., 18F-fluoride
PET/CT for the staging of prostate cancer. Thus, there is
a rationale for conducting properly designed DTA studies
before making changes in clinical practice. If superiority is
clearly evident, the work required to demonstrate it is
limited. The design and size of this study ensure that the
results will be recognised both nationally and internation-
ally; the perspective may be the general use of 18F-fluoride




ADT: androgen deprivation therapy; BS: planar bone scintigraphy;
DTA: diagnostic test accuracy; GRADE: the grading of recommendations
assessment, development and evaluation; PET/CT: positron emission
tomography/computed tomography; PSA: prostate specific antigen;
RCT: randomised controlled trial; SPECT/CT: single photon emission
computed tomography/computed tomography; STARD: standard for the
reporting of diagnostic accuracy studies.
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